Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James K Burmester

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Clinical Medicine & Research|June 3, 2005
The promise of molecular profiling for cancer identification and treatmentDeanna Cross, James K Burmester
WMJ : Official Publication of the State Medical Society of Wisconsin|February 1, 2003
A genetic approach to the problem of chronic wasting disease in WisconsinDeanna Cross, James K Burmester
Clinical Medicine & Research|September 22, 2006
Gene therapy for cancer treatment: past, present and futureDeanna Cross, James K Burmester
Clinical Medicine & Research|June 3, 2005
Medical applications of transforming growth factor-betaKathleen C Flanders, James K Burmester
Clinical Medicine & Research|May 10, 2013
Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?Ingrid Glurich, Richard L Berg, James K Burmester
Heart Failure Reviews|November 11, 2008
Understanding the pharmacogenetic approach to warfarin dosingIngrid Glurich, James K Burmester, Michael D Caldwell
Journal of Cancer|May 17, 2013
Modeling efficacy of bevacizumab treatment for metastatic colon cancerRezwan Islam, Po-Huang Chyou, James K Burmester
Pharmacogenetics and Genomics|May 19, 2005
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damageRussell A Wilke, Jason H Moore, James K Burmester
Clinical Medicine & Research|May 29, 2012
Evaluation of a mitochondrial DNA mutation in maternally inherited and sporadic cases of Dupuytren diseaseEric R Anderson, James K Burmester, Michael D Caldwell
WMJ : Official Publication of the State Medical Society of Wisconsin|September 21, 2002
Pesticide exposure, host susceptibility factors and risk of Parkinson's disease: an introduction to a work in progressAnne R Greenlee, James K Burmester, Bradley C Hiner
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Clinical Medicine & Research|June 3, 2005
The promise of molecular profiling for cancer identification and treatmentDeanna Cross, James K Burmester
WMJ : Official Publication of the State Medical Society of Wisconsin|February 1, 2003
A genetic approach to the problem of chronic wasting disease in WisconsinDeanna Cross, James K Burmester
Clinical Medicine & Research|September 22, 2006
Gene therapy for cancer treatment: past, present and futureDeanna Cross, James K Burmester
Clinical Medicine & Research|June 3, 2005
Medical applications of transforming growth factor-betaKathleen C Flanders, James K Burmester
Clinical Medicine & Research|May 10, 2013
Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?Ingrid Glurich, Richard L Berg, James K Burmester
Heart Failure Reviews|November 11, 2008
Understanding the pharmacogenetic approach to warfarin dosingIngrid Glurich, James K Burmester, Michael D Caldwell
Journal of Cancer|May 17, 2013
Modeling efficacy of bevacizumab treatment for metastatic colon cancerRezwan Islam, Po-Huang Chyou, James K Burmester
Pharmacogenetics and Genomics|May 19, 2005
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damageRussell A Wilke, Jason H Moore, James K Burmester
Clinical Medicine & Research|May 29, 2012
Evaluation of a mitochondrial DNA mutation in maternally inherited and sporadic cases of Dupuytren diseaseEric R Anderson, James K Burmester, Michael D Caldwell
WMJ : Official Publication of the State Medical Society of Wisconsin|September 21, 2002
Pesticide exposure, host susceptibility factors and risk of Parkinson's disease: an introduction to a work in progressAnne R Greenlee, James K Burmester, Bradley C Hiner
Pageof 5